| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kristin Heuschkel, Kim P C Kuyper. Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review. Frontiers in psychiatry. vol 11. 2020-09-28. PMID:32296353. |
to that end, the individual effects of mm and psilocybin, and their underlying working mechanisms, were compared on a non-exhaustive selection of six prominent psychological and biological processes that are well known to show impairments in patients suffering from major depression disorder, that is mood, executive functioning, social skills, neuroplasticity, core neural networks, and neuroendocrine and neuroimmunological levels. |
2020-09-28 |
2023-08-13 |
Not clear |
| Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R Hutso. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. vol 284. 2020-09-11. PMID:31931272. |
the experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. |
2020-09-11 |
2023-08-13 |
Not clear |
| Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R Hutso. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. vol 284. 2020-09-11. PMID:31931272. |
the current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. |
2020-09-11 |
2023-08-13 |
Not clear |
| Simon B Goldberg, Brian T Pace, Christopher R Nicholas, Charles L Raison, Paul R Hutso. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry research. vol 284. 2020-09-11. PMID:31931272. |
results tentatively support future research on psilocybin for the treatment of anxiety and depression. |
2020-09-11 |
2023-08-13 |
Not clear |
| Janis Fricke, Alexander Sherwood, Robert Kargbo, Andrew Orry, Felix Blei, Andreas Naschberger, Bernhard Rupp, Dirk Hoffmeiste. Enzymatic Route toward 6-Methylated Baeocystin and Psilocybin. Chembiochem : a European journal of chemical biology. vol 20. issue 22. 2020-08-21. PMID:31150155. |
the pharmaceutical interest in psilocybin as a treatment option against depression and anxiety is currently being investigated in advanced clinical trials. |
2020-08-21 |
2023-08-13 |
Not clear |
| Janis Fricke, Robert Kargbo, Lars Regestein, Claudius Lenz, Gundela Peschel, Miriam A Rosenbaum, Alexander Sherwood, Dirk Hoffmeiste. Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin. Chemistry (Weinheim an der Bergstrasse, Germany). vol 26. issue 37. 2020-07-30. PMID:32101345. |
psilocybin, the principal indole alkaloid of psilocybe mushrooms, is currently undergoing clinical trials as a medication against treatment-resistant depression and major depressive disorder. |
2020-07-30 |
2023-08-13 |
Not clear |
| Richard E Doblin, Merete Christiansen, Lisa Jerome, Brad Burg. The Past and Future of Psychedelic Science: An Introduction to This Issue. Journal of psychoactive drugs. vol 51. issue 2. 2020-05-22. PMID:31132970. |
this research includes clinical trials with mdma-assisted therapy for the treatment of ptsd, alcoholism, and social anxiety, and psilocybin clinical studies for depression and addiction, as well as the ability of psychedelics to catalyze spiritual or mystical experiences and inspire creativity, and into the neuroscientific understanding the effects of psychedelic substances on our nervous system. |
2020-05-22 |
2023-08-13 |
Not clear |
| Rémi Corne, Raymond Mongea. [Neurotrophic mechanisms of psychedelic therapy]. Biologie aujourd'hui. vol 213. issue 3-4. 2020-05-18. PMID:31829932. |
serotonergic psychedelics such as psilocybin and lysergic acid diethylamide (lsd) are gaining attention as potential treatments for depression and addiction, similarly to 3,4-methylenedioxymethamphetamine (mdma) for post-traumatic stress disorder (ptsd), and ibogaine for addiction. |
2020-05-18 |
2023-08-13 |
Not clear |
| David Nut. Psychedelic drugs-a new era in
psychiatry?
. Dialogues in clinical neuroscience. vol 21. issue 2. 2020-04-03. PMID:31636488. |
these findings have led to the european medicines agency approving psilocybin for a phase 3 study in treatment-resistant depression and the food and drug administration for ptsd with mdma. |
2020-04-03 |
2023-08-13 |
Not clear |
| Oskar Jefsen, Kristoffer Højgaard, Sofie Laage Christiansen, Betina Elfving, David John Nutt, Gregers Wegener, Heidi Kaastrup Mülle. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta neuropsychiatrica. vol 31. issue 4. 2020-01-09. PMID:31106729. |
psilocybin is a serotonin receptor agonist with a therapeutic potential for treatment-resistant depression and other psychiatric illnesses. |
2020-01-09 |
2023-08-13 |
rat |
| Oskar Jefsen, Kristoffer Højgaard, Sofie Laage Christiansen, Betina Elfving, David John Nutt, Gregers Wegener, Heidi Kaastrup Mülle. Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat. Acta neuropsychiatrica. vol 31. issue 4. 2020-01-09. PMID:31106729. |
we investigated whether the administration of psilocybin had an antidepressant-like effect in a rat model of depression. |
2020-01-09 |
2023-08-13 |
rat |
| Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer, David Erritzoe, Brice Ozenne, Gitte M Knudse. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 44. issue 7. 2019-12-10. PMID:30685771. |
the main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. |
2019-12-10 |
2023-08-13 |
human |
| Haden A Geiger, Madeline G Wurst, R Nathan Daniel. DARK Classics in Chemical Neuroscience: Psilocybin. ACS chemical neuroscience. vol 9. issue 10. 2019-11-18. PMID:29956917. |
recently, however, preliminary studies with psilocybin have shown promise as potential for the treatment of obsessive compulsive disorder, alcohol addiction, tobacco addiction, and major depressive disorder, and the treatment of depression in terminally ill cancer patients. |
2019-11-18 |
2023-08-13 |
Not clear |
| Michael J Wasko, Paula A Witt-Enderby, Christopher K Surrat. DARK Classics in Chemical Neuroscience: Ibogaine. ACS chemical neuroscience. vol 9. issue 10. 2019-11-18. PMID:30216039. |
ibogaine analogs may also hold promise for treating anxiety and depression via the "psychedelic-assisted therapy" approach that employs hallucinogens including psilocybin and methylenedioxymethamphetamine ("ecstasy"). |
2019-11-18 |
2023-08-13 |
Not clear |
| Taylor Lyons, Robin L Carhart-Harri. Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England). vol 32. issue 7. 2019-10-31. PMID:29338538. |
increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. |
2019-10-31 |
2023-08-13 |
human |
| D Erritzoe, L Roseman, M M Nour, K MacLean, M Kaelen, D J Nutt, R L Carhart-Harri. Effects of psilocybin therapy on personality structure. Acta psychiatrica Scandinavica. vol 138. issue 5. 2019-10-11. PMID:29923178. |
to explore whether psilocybin with psychological support modulates personality parameters in patients suffering from treatment-resistant depression (trd). |
2019-10-11 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran, David J Nut. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports. vol 7. issue 1. 2019-07-01. PMID:29030624. |
psilocybin for treatment-resistant depression: fmri-measured brain mechanisms. |
2019-07-01 |
2023-08-13 |
Not clear |
| Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran, David J Nut. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific reports. vol 7. issue 1. 2019-07-01. PMID:29030624. |
here, cerebral blood flow (cbf) and blood oxygen-level dependent (bold) resting-state functional connectivity (rsfc) were measured with functional magnetic resonance imaging (fmri) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (trd). |
2019-07-01 |
2023-08-13 |
Not clear |
| Clinton E Cana. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Handbook of experimental pharmacology. vol 252. 2019-06-13. PMID:29532180. |
recent, well-controlled - albeit small-scale - clinical trials show that serotonergic psychedelics, including psilocybin and lysergic acid diethylamide, possess great promise for treating psychiatric disorders, including treatment-resistant depression. |
2019-06-13 |
2023-08-13 |
Not clear |
| Phil Cowe. Altered states: psilocybin for treatment-resistant depression. The lancet. Psychiatry. vol 3. issue 7. 2019-05-30. PMID:27210032. |
altered states: psilocybin for treatment-resistant depression. |
2019-05-30 |
2023-08-13 |
Not clear |